

Select mdx helps identify patients at-risk for clinically significant cancer

Identify patients who may
benefit from biopsy

mdxhealth®

Superior care made easy.

Streamline your workflow while
maintaining a high level of care.
Mdxhealth delivers comprehensive
solutions with dedicated support.



Challenges with the Standard of Care in identifying CSPCa

- Only about 25% of men with an elevated PSA are diagnosed with prostate cancer upon biopsy.¹
- Up to 70% of new cancer diagnoses are low-grade (GS 6) not likely to alter quality of life.²
- Approximately half of all men who undergo mpMRI do not have clinically significant prostate cancer.³

Accurately identify patients at-risk for CSPCa before biopsy

Select mdx is a urine test to help improve the earlier detection of clinically significant prostate cancer. It provides binary test results for men with an elevated PSA (≥ 3 ng/mL), improving patient selection for biopsy.⁴



Rule out men that may avoid biopsy/MRI



Rule in men that may benefit from biopsy/MRI



Helps identify men at risk for GS ≥ 7 prostate cancer⁴



95% NPV for GS ≥ 7 instills confidence the patient is not at risk for CSPCa⁴



Helps avoid ~50% of potentially unnecessary biopsies⁴



Patient urine sample



Biomarkers

- DLX1: progression gene⁵
- HOXC6: cell proliferation gene⁶



Clinical risk factors

- Age
- Prostate volume
- PSA
- DRE

Select mdx



Low risk: May avoid biopsy/MRI
Low risk for GS ≥ 7 PCa



Elevated risk: Consider biopsy/MRI
Increased risk for GS ≥ 7 PCa



Learn how Select mdx fills the gap left by inconsistent screening guidelines to improve the Standard of Care

Improved workflow for better outcomes

Introducing the simple urine test into your pre-biopsy workflow helps determine patient risk for detecting clinically significant prostate cancer upon biopsy.



Patient
Elevated PSA and/or abnormal DRE
No PSA level restrictions

Select mdx

+ Elevated risk for GS ≥ 7 PCa

Biopsy/MRI

- Low risk for GS ≥ 7 PCa

Routine PSA follow-up

Published Scientific Data

Studies validate the performance of Select mdx to guide initial biopsy decisions

The 2-gene-based urine assay demonstrates high sensitivity (89%), AUC (0.85) and NPV (95%) for the accurate detection of clinically significant prostate cancer. These data support the use of Select mdx to help guide initial prostate biopsy decisions and, further, the test correlates to mpMRI outcomes.



Industry-leading clinical performance




Included in NCCN Guidelines




Covered by Medicare


Select mdx score correlates with mpMRI outcome⁷



Select mdx score correlates with PCa grading⁸



Select mdx outperforms PCPTRCv2⁴



Xpert One Support is founded on personal attention, responsiveness, and commitment to customer satisfaction. Our Xperts are truly experts on mdxhealth products and processes, from specimen requirements and shipping logistics to clinical insights. Together with your mdxhealth Molecular Diagnostic Specialist, Xpert One Support strives to make your mdxhealth experience the best it can be.

Comprehensive Solutions, Dedicated Support



Xpress Response Time

Our goal is to respond to your phone or e-mail inquiry within 24 hours or less.



Xtraordinary Convenience

Optimize your workflow by customizing your support with specimen shipping, automated supplies replenishment, and more.



Xpertise On Demand

Answer your questions with clinical resources and industry thought leaders. In addition, our Patient Education Program also provides valuable support to answer questions and educate patients on general prostate health and cancer.



Xceptional Compassion

Our Patient First Promise ensures mdxhealth tests are accessible and affordable for all patients. If you're facing financial challenges, contact an Xpert One Support patient advocate to find the right assistance options for you.

Easy to order



mdxhealth obtains archived tissue from pathology



No additional office visit for patient required



Covered by Medicare and most private payors

Get in touch to see how mdxhealth can make your everyday more efficient:



866-259-5644



info@mdxhealth.com

References

- Haese A, et al. Multicenter optimization and validation of a 2-gene mRNA urine test for detection of clinically significant prostate cancer prior to initial prostate biopsy. *Journal of Urology* 2019.
- Schroder F, et al. Screening and prostate-cancer mortality in a randomized European study. *New England Journal of Medicine* 2009.
- Barry MJ. Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer. *New England Journal of Medicine* 2001.
- Jalloh M, et al. Racial variation in prostate cancer upgrading and upstaging among men with low-risk clinical characteristics. *European Urology* 2015.
- Punnen S, et al. The epidemiology of high-risk prostate cancer. *Current Opinion in Urology* 2013.
- Moldovan PC, et al. What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel. *European Urology* 2017.
- Van Neste L, et al. Detection of High-grade Prostate Cancer using a urinary molecular biomarker-based risk score. *European Urology* 2016.
- Hendriks RJ, et al. A urinary biomarker-based risk score correlates with multiparametric MRI for prostate cancer detection. *The Prostate* 2017.
- Merlo GR, et al. Multiple functions of DLX genes. *Journal of International Development* 2000.
- Hamid AR, et al. The role of HOXC6 in prostate cancer development. *The Prostate* 2015.
- Govers T, et al. Cost Effectiveness of SelectMDx in Prostate Cancer Risk Assessment. *Journal of Urology* 2018.

Mdxhealth is regulated under the Clinical Laboratory Improvement Amendments (CLIA) and the College of American Pathologists (CAP) as an accredited laboratory to perform high complexity clinical testing. This test was developed, and its performance characteristics determined by mdxhealth. It has not been cleared or approved by the US Food and Drug Administration. The FDA has determined such clearance or approval is not necessary.